TSE:GUD Knight Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Knight Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. C$5.42 +0.09 (+1.69%) (As of 06/28/2022 12:00 AM ET) Add Compare Share Today's RangeC$5.33▼C$5.4250-Day RangeC$5.07▼C$5.4652-Week RangeC$5.01▼C$5.74Volume141,847 shsAverage Volume210,378 shsMarket CapitalizationC$624.87 millionP/E RatioN/ADividend YieldN/APrice TargetC$7.00 ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesHeadlinesSocial Media View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive GUD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Knight Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address GUD Stock Forecast (MarketRank)Overall MarketRank™2.14 out of 5 starsAnalyst Opinion: 3.4Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 - 3.4 Analyst's Opinion Consensus RatingKnight Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of C$7.00, Knight Therapeutics has a forecasted upside of 29.2% from its current price of C$5.42.Amount of Analyst CoverageKnight Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Community Rank Outperform VotesKnight Therapeutics has received 106 “outperform” votes. (Add your “outperform” vote.)Underperform VotesKnight Therapeutics has received 31 “underperform” votes. (Add your “underperform” vote.)Community SentimentKnight Therapeutics has received 77.37% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Knight Therapeutics and other stocks. Vote “Outperform” if you believe GUD will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GUD will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldKnight Therapeutics does not currently pay a dividend.Dividend GrowthKnight Therapeutics does not have a long track record of dividend growth. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Knight Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought C$406,709.00 in company stock and sold C$0.00 in company stock. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Knight Therapeutics is -98.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Knight Therapeutics is -98.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioDue to a projected decrease in earnings for Knight Therapeutics, their PEG ratio cannot be calculated.Price to Book Value per Share RatioKnight Therapeutics has a P/B Ratio of 0.76. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Knight Therapeutics (TSE:GUD)Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. It offers Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib to treat metastatic cholangiocarcinoma; Trelstar for advanced prostate cancer and for pain associated with endometriosis; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven for metastatic breast cancer and doft tissue sarcoma; and Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma. The company also provides Ladevina for multiple myeloma, myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Exelon for mild to moderately severe dementia; and Ibsrela for the treatment of irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk to treat biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms associated with menopause in women with intact uteri; Fibridoner to treat idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection in patients with cystic fibrosis; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, the company finances other life science companies; and invests in life sciences venture capital funds. Knight Therapeutics Inc. was incorporated in 2013 and is headquartered in Montreal, Canada.Read More GUD Stock News HeadlinesJune 21, 2022 | americanbankingnews.comKnight Therapeutics Inc. (TSE:GUD) Director Samira Sakhia Acquires 19,455 Shares of StockJune 20, 2022 | americanbankingnews.comKnight Therapeutics Inc. (TSE:GUD) Insider Buys C$93,240.00 in StockJune 11, 2022 | americanbankingnews.comBrokerages Set Knight Therapeutics Inc. (TSE:GUD) Price Target at C$7.00June 11, 2022 | americanbankingnews.comAnalysts Set Knight Therapeutics Inc. (TSE:GUD) Price Target at C$7.00June 10, 2022 | theglobeandmail.comInsiders are buying as Knight Therapeutics consolidatesJune 7, 2022 | finance.yahoo.comKnight to Present at the 2022 BIO International Convention in San DiegoMay 24, 2022 | markets.businessinsider.comKnight Therapeutics Secures Rights To Rigel's Fostamatinib In Latin AmericaMay 24, 2022 | finance.yahoo.comKnight Therapeutics Enters into Exclusive License and Supply Agreements with Rigel Pharmaceuticals to Commercialize Fostamatinib in Latin AmericaMay 12, 2022 | finance.yahoo.comKnight Therapeutics Reports First Quarter 2022 ResultsMarch 25, 2022 | finance.yahoo.comKnight Therapeutics Inc. places on The Globe and Mail’s third-annual Women Lead Here benchmark of executive gender diversityMarch 24, 2022 | finance.yahoo.comKnight Therapeutics Reports Fourth Quarter and Year-End 2021 Results and Provides 2022 Revenue GuidanceFebruary 22, 2022 | finance.yahoo.comHere's Why I Think Knight Therapeutics (TSE:GUD) Might Deserve Your Attention TodayJanuary 6, 2022 | theglobeandmail.comStocks in play: Knight Therapeutics IncSee More Headlines Industry, Sector and Symbol Stock ExchangeTSE Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolTSE:GUD CUSIPN/A CIKN/A Webwww.gud-knight.com Phone514-484-4483FaxN/AEmployees660Year FoundedN/ACompany Calendar Last Earnings5/12/2022Today6/28/2022Next Earnings (Estimated)8/12/2022Price Target and Rating Average Stock Price ForecastC$7.00 High Stock Price ForecastC$7.50 Low Stock Price ForecastC$5.30 Forecasted Upside/Downside+29.2%Consensus RatingModerate Buy Rating Score (0-4)2.83333333333333 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth-537.5Net IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio5.64 Current Ratio2.73 Quick Ratio2.05 Sales & Book Value Annual SalesC$261.22 million Price / Sales2.39 Cash FlowC$1.51 per share Price / Cash Flow3.59 Book ValueC$7.12 per share Price / Book0.76Miscellaneous Outstanding Shares115,289,000Free FloatN/AMarket CapC$624.87 million OptionableNot Optionable BetaN/A Knight Therapeutics Frequently Asked Questions Should I buy or sell Knight Therapeutics stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Knight Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" Knight Therapeutics stock. View analyst ratings for Knight Therapeutics or view top-rated stocks. What is Knight Therapeutics' stock price forecast for 2022? 6 Wall Street analysts have issued 12-month price objectives for Knight Therapeutics' shares. Their GUD stock forecasts range from C$5.30 to C$7.50. On average, they predict Knight Therapeutics' stock price to reach C$7.00 in the next twelve months. This suggests a possible upside of 29.2% from the stock's current price. View analysts' price targets for Knight Therapeutics or view top-rated stocks among Wall Street analysts. How has Knight Therapeutics' stock price performed in 2022? Knight Therapeutics' stock was trading at C$5.30 at the beginning of the year. Since then, GUD stock has increased by 2.3% and is now trading at C$5.42. View the best growth stocks for 2022 here. When is Knight Therapeutics' next earnings date? Knight Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022. View our earnings forecast for Knight Therapeutics. How were Knight Therapeutics' earnings last quarter? Knight Therapeutics Inc. (TSE:GUD) announced its earnings results on Thursday, May, 12th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.02. The company had revenue of $63.81 million for the quarter, compared to the consensus estimate of $52.80 million. View Knight Therapeutics' earnings history. Who are Knight Therapeutics' key executives? Knight Therapeutics' management team includes the following people: Mr. Jonathan Ross Goodman B.A., BA, L.L.B., LLB, M.B.A., MBA, Exec. Chairman (Age 53, Pay $455.25k)Ms. Samira Sakhia BCom, CA, CPA, MBA, Pres, CEO & Director (Age 54, Pay $691.66k)Mr. Arvind Utchanah, Chief Financial OfficerMs. Amal Khouri M.B.A., Chief Bus. OfficerMr. Jeff Martens, Global VP CommercialMr. Leopoldo Bosano, Vice-Pres of Manufacturing & OperationsMs. Daniela Marino, Global VP of Legal & ComplianceMs. Susan Caroline Emblem, Global VP of HRMs. Jody Engel, Sr. Director of Bus. Devel. Who are some of Knight Therapeutics' key competitors? Some companies that are related to Knight Therapeutics include Canopy Growth (WEED), Hydropothecary (THCX), Aurora Cannabis (ACB), Amryt Pharma (AMYT), HLS Therapeutics (HLS), OrganiGram (OGI), Benchmark (BMK), Supreme Cannabis (FIRE), ESSA Pharma (EPI), ICC Labs (ICC), Leaf Mobile (LEAF), Medexus Pharmaceuticals (MDP), HEXO (HEXO), BioSyent (RX) and Green Organic Dutchman (TGOD). View all of GUD's competitors. What other stocks do shareholders of Knight Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Knight Therapeutics investors own include Constellation Software (CSU), Bombardier, Inc. Class B (BBD.B), Brookfield Infrastructure Partners (BIP.UN), Enbridge (ENB), Spin Master (TOY), Alimentation Couche-Tard (ATD.B), Chemtrade Logistics Income Fund (CHE.UN), Canadian National Railway (CNR), Dollarama (DOL) and Extendicare (EXE). What is Knight Therapeutics' stock symbol? Knight Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "GUD." How do I buy shares of Knight Therapeutics? Shares of GUD and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. What is Knight Therapeutics' stock price today? One share of GUD stock can currently be purchased for approximately C$5.42. How much money does Knight Therapeutics make? Knight Therapeutics (TSE:GUD) has a market capitalization of C$624.87 million and generates C$261.22 million in revenue each year. How many employees does Knight Therapeutics have? Knight Therapeutics employs 660 workers across the globe. How can I contact Knight Therapeutics? The official website for Knight Therapeutics is www.gud-knight.com. The company can be reached via phone at 514-484-4483. This page (TSE:GUD) was last updated on 6/28/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
